ASH 2022 | The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, summarizes the results of a recent study investigating the outcomes of patients with multiple myeloma undergoing allogeneic transplantation in patients, explaining that high relapse rates and mortality associated with graft-versus-host disease (GvHD) have been observed. Following this, Dr Gertz suggests that patients may benefit more from novel drugs such as pomalidomide, daratumumab, carfilzomib, and teclistamab. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Ionis/Akcea: Other: personal fees; Prothena: Other: personal fees; Sanofi: Other: personal fees; Janssen: Other: personal fees; Aptitude Healthgrants: Other: personal fees; Ashfield: Other: personal fees; Juno: Other: personal fees; Physicians Education Resource: Other: personal fees; Abbvie: Membership on an entity’s Board of Directors or advisory committees, Other: personal fees from Data Safety Monitoring Board; Johnson & Johnson: Other: personal fees; Celgene: Other: personal fees; Research to Practice: Other: personal fees; Sorrento: Other: personal fees; i3Health: Other: Development of educational materials for i3Health.
